The estimated Net Worth of Andreas Maetzel is at least $438 mil dollars as of 27 April 2021. Andreas Maetzel owns over 88,030 units of KalVista Pharmaceuticals Inc stock worth over $438,298 and over the last 12 years he sold KALV stock worth over $0. In addition, he makes $0 as Senior Vice President - Medical at KalVista Pharmaceuticals Inc.
Andreas has made over 2 trades of the KalVista Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 88,030 units of KALV stock worth $809,876 on 27 April 2021.
The largest trade he's ever made was exercising 88,030 units of KalVista Pharmaceuticals Inc stock on 27 April 2021 worth over $809,876. On average, Andreas trades about 8,457 units every 68 days since 2013. As of 27 April 2021 he still owns at least 40,886 units of KalVista Pharmaceuticals Inc stock.
You can see the complete history of Andreas Maetzel stock trades at the bottom of the page.
Dr. Andreas Maetzel M.D. Ph.D. serves as Senior Vice President - Medical of the Company. Dr. Maetzel joined as our Senior Vice President of Medical in March 2017. Dr. Maetzel was most recently Vice President, Global Medical Affairs at BioCryst Pharmaceuticals from August 2014 to February 2017. Prior to that he was Vice President, Clinical Development & Regulatory Affairs at Cornerstone Therapeutics Inc from May 2013 to February 2014. From September 2011 to April 2013, Dr. Maetzel held a clinical development role at BioCryst. He previously held positions in health technology assessment strategy at Amgen and in strategy consulting. He is Visiting Scientist at Charité Hospital Berlin, and maintains an appointment as Adjunct Professor at Institute for Health Policy, Management & Evaluation, University of Toronto. Dr. Maetzel obtained both a Ph.D. and an M.Sc. in Clinical Epidemiology from the University of Toronto and a Dr. Med. at the University of Hannover, Germany.
Andreas Maetzel is 56, he's been the Senior Vice President - Medical of KalVista Pharmaceuticals Inc since 2017. There are 8 older and 8 younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.
Andreas's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.
Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ..., eRajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include: